Bajaj Nivesh Reports 9.7% Revenue Growth in Q2 FY27, Net Profit Rises 9.8%
Bajaj Nivesh reported higher revenue and profit for the second quarter of FY27, while its half-yearly results showed a modest increase in revenue and a decline in profit compared with the corresponding period of the previous year.
Bajaj Nivesh Reports Growth in Quarterly Earnings
For Q2 FY27, revenue from operations increased to Rs.297.36 crore from Rs.271.02 crore in Q2 FY26, registering growth of approximately 9.7%. Net profit rose to Rs.293.27 crore from Rs.267.07 crore in the year-ago quarter, an increase of around 9.8%.
Basic and diluted earnings per share (EPS) also improved to Rs.256.61 in Q2 FY27, compared with Rs.233.69 in the corresponding quarter of the previous financial year.
The half-yearly performance was mixed. Revenue from operations increased slightly to Rs.302.77 crore in H1 FY27 from Rs.300.29 crore in H1 FY26. However, profit after tax declined to Rs.296.59 crore from Rs.302.43 crore. Dividend income remained the primary revenue contributor, accounting for Rs.289.81 crore during the first half of FY27.
Bajaj Nivesh Financial Highlights and Balance Sheet Position
| Financial Metric | Reported Figures |
|---|---|
| Q2 FY27 Revenue from Operations | Rs.297.36 crore, compared with Rs.271.02 crore in Q2 FY26 |
| Q2 FY27 Net Profit | Rs.293.27 crore, compared with Rs.267.07 crore in Q2 FY26 |
| Basic and Diluted EPS | Rs.256.61, compared with Rs.233.69 in Q2 FY26 |
| H1 FY27 Revenue from Operations | Rs.302.77 crore, compared with Rs.300.29 crore in H1 FY26 |
| H1 FY27 Profit After Tax | Rs.296.59 crore, compared with Rs.302.43 crore in H1 FY26 |
| H1 FY27 Dividend Income | Rs.289.81 crore |
| Total Assets | Rs.36,540.54 crore as of September 30, 2026 |
| Total Equity | Rs.32,411.31 crore, including other equity of Rs.32,399.88 crore |
| Book Value per Share | Rs.28,360 as of September 30, 2026 |
What to Watch Next
Future results will indicate whether Bajaj Nivesh can sustain its quarterly earnings growth and improve its half-yearly profitability. Changes in dividend income, the size of its asset base and its capital position may also be relevant indicators to monitor in upcoming reporting periods.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Balkrishna Industries Signs Strategic Partnership with Pirelli for Premium Car Tyres in India
Balkrishna Industries Limited (BKT) has signed a strategic agreement with Pirelli to expand its presence in India's premium passenger car tyre market. Under the agreement, BKT will produce up to 800,000 Pirelli-branded premium car tyres by 2030. Production will take place at one of BKT's newly constructed plants, equipped with advanced technology and designed to meet Pirelli's quality standards. The agreement also provides for a potential 50-50 joint venture to build a new production plant for high-value car tyres for domestic and international markets. The partnership aims to help both companies benefit from the expected growth in India's premium car tyre market.
Corona Remedies Receives ANVISA GMP Certification for Two Manufacturing Facilities
Corona Remedies Limited has received Good Manufacturing Practice (GMP) Compliance Certification from Brazil’s Health Regulatory Agency, ANVISA, for its Oral Solid Dosage (OSD) manufacturing facility and Hormone manufacturing facility, both located at Bhayla, Ahmedabad, Gujarat. The company disclosed the development to BSE Limited and the National Stock Exchange of India Limited on October 22, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The certification may support the company's efforts to expand its presence in international pharmaceutical markets, subject to applicable regulatory requirements.
Magellanic Cloud Subsidiary Emerges as L1 Bidder for Bank of Maharashtra Tender Worth Rs.115 Crore
Magellanic Cloud Limited has announced that its wholly owned subsidiary, Provigil Surveillance Limited, has emerged as the lowest bidder (L1) for a Bank of Maharashtra tender valued at approximately Rs.115 crore. The project involves deploying electronic surveillance systems across more than 1,550 bank sites, with the final contract award subject to the bank issuing a formal order.